Topics

Lilly's Taltz beats Janssen's Tremfya at Phase 4 in plaque psoriasis

05:45 EDT 15 Aug 2019 | Pharmafile

Eli Lilly has unveiled new Phase 4 data supporting the efficacy and safety of Taltz (ixekizumab) when compared to Janssen’s Tremfya (guselkumab), showing that the former met all primary and secondary endpoints in the treatment of moderate to severe plaque psoriasis (PsO).

The 1,027-participant trial is the first to directly compare an IL-17A inhibitor to an IL-23/p19 inhibitor using the Psoriasis Area Severity Index (PASI) 100 score as a primary endpoint to assess their efficacy.

read more

Original Article: Lilly's Taltz beats Janssen's Tremfya at Phase 4 in plaque psoriasis

NEXT ARTICLE

More From BioPortfolio on "Lilly's Taltz beats Janssen's Tremfya at Phase 4 in plaque psoriasis"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Psoriasis
Psoriasis is a common skin condition affecting 2-3% of the population of the United Kingdom, where the skins replacement process is sped taking 2-6 days instead of the usual 21 - 28 days for the replacement of skin cells. Patients experience an accumulat...